This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial . The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury (DILI), chronic hepatitis B (CHB), intrahepatic cholestatic liver injury, etc.).
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Adverse events (AE), serious adverse events (SAE)
Timeframe: 7 days of administration in the first stage and 14 days of administration in the second stage
Adverse events (AE), serious adverse events (SAE)
Timeframe: followed up for 28 days in the first stage and followed up for 14 days in the second stage
clinical laboratory tests ：blood routine
Timeframe: 7 days of administration in the first stage and 14 days of administration in the second stage
clinical laboratory tests ：blood routine
Timeframe: followed up for 28 days in the first stage and followed up for 14 days in the second stage
clinical laboratory tests ：blood biochemistry
Timeframe: 7 days of administration in the first stage and 14 days of administration in the second stage
clinical laboratory tests ：blood biochemistry
Timeframe: followed up for 28 days in the first stage and followed up for 14 days in the second stage
clinical laboratory tests : urine routine
Timeframe: 7 days of administration in the first stage and 14 days of administration in the second stage
clinical laboratory tests : urine routine
Timeframe: followed up for 28 days in the first stage and followed up for 14 days in the second stage
clinical laboratory tests ：blood coagulation function
Timeframe: 7 days of administration in the first stage and 14 days of administration in the second stage
clinical laboratory tests ：blood coagulation function
Timeframe: followed up for 28 days in the first stage and followed up for 14 days in the second stage
12-lead electrocardiogram (ECG)
Timeframe: 7 days of administration in the first stage and 14 days of administration in the second stage
12-lead electrocardiogram (ECG)
Timeframe: followed up for 28 days in the first stage and followed up for 14 days in the second stage
All-cause mortality
Timeframe: 28 days after completion of dosing in the third stage
All-cause mortality
Timeframe: 90 days after completion of dosing in the third stage